tanshinone has been researched along with chitosan in 10 studies
| Studies (tanshinone) | Trials (tanshinone) | Recent Studies (post-2010) (tanshinone) | Studies (chitosan) | Trials (chitosan) | Recent Studies (post-2010) (chitosan) |
|---|---|---|---|---|---|
| 1,445 | 10 | 1,033 | 27,648 | 232 | 21,257 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 6 (60.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pan, LQ; Wang, K; Zhao, HR; Zhao, Y | 1 |
| Jia, XB; Jiang, YR; Jin, X; Liu, QY; Zhang, ZH | 1 |
| Duan, J; Ma, L; Sun, Y; Wang, D; Wu, Y | 1 |
| Li, G; Lin, X; Luo, C; Qi, C; Yang, Q | 1 |
| Chen, G; Chen, X; Hu, H; Liang, Y; Wen, L; Yu, H; Zeng, P | 1 |
| Guo, Y; Hu, R; Hua, L; Qin, W; Wang, Y; Yang, Y; Zhang, X | 1 |
| Wu, N; Yu, J; Zheng, M; Zheng, X | 1 |
| Chang, Y; Du, L; Huang, Y; Kang, X; Liu, Y; Wang, J; Wang, S; Zhang, L; Zhang, X; Zhao, Y | 1 |
| Gao, H; Liang, H; Liu, J; Muhammad, T; Wang, M | 1 |
| Dai, F; Li, J; Lu, M; Ma, L; Qiu, T; Song, F; Tong, M; Zhang, X | 1 |
10 other study(ies) available for tanshinone and chitosan
| Article | Year |
|---|---|
Novel sustained-release implant of herb extract using chitosan.
Topics: Abietanes; Animals; Biocompatible Materials; Biodegradation, Environmental; Chitin; Chitosan; Chromatography, High Pressure Liquid; Delayed-Action Preparations; In Vitro Techniques; Male; Phenanthrenes; Plant Extracts; Plant Preparations; Plants, Medicinal; Polymers; Rats; Rats, Wistar; Salvia miltiorrhiza; Time Factors; Wound Healing | 2002 |
Enhanced dissolution and oral bioavailability of tanshinone IIA base by solid dispersion system with low-molecular-weight chitosan.
Topics: Abietanes; Administration, Oral; Animals; Area Under Curve; Biological Availability; Chitosan; Drug Carriers; Male; Molecular Weight; Rats; Rats, Sprague-Dawley; Solubility | 2013 |
Synthesis, characterization and anticancer activity of tanshinone I grafted low molecular chitosan.
Topics: Abietanes; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Survival; Chitosan; Humans; Membrane Potential, Mitochondrial; PC12 Cells; Rats | 2017 |
Preparation and drug release property of tanshinone IIA loaded chitosan-montmorillonite microspheres.
Topics: Abietanes; Bentonite; Biocompatible Materials; Cell Survival; Chitosan; Diffusion; Drug Delivery Systems; Drug Liberation; Hydrophobic and Hydrophilic Interactions; Microspheres | 2019 |
A Tanshinone IIA loaded hybrid nanocomposite with enhanced therapeutic effect for otitis media.
Topics: Abietanes; Animals; Anti-Bacterial Agents; Bacteria; Chitosan; Female; Guinea Pigs; Male; Metal Nanoparticles; Muramidase; Nanocomposites; Otitis Media; Silver | 2020 |
Preparation, evaluation, and in vitro release of chitosan-alginate tanshinone self-microemulsifying sustained-release microcapsules.
Topics: Abietanes; Alginates; Capsules; Chitosan; Delayed-Action Preparations; Humans | 2021 |
Preparation of water-soluble chitosan/poly-gama-glutamic acid-tanshinone IIA encapsulation composite and its in vitro/in vivo drug release properties.
Topics: Abietanes; Animals; Anti-Inflammatory Agents; Area Under Curve; Chitosan; Chromatography, High Pressure Liquid; Drug Carriers; Drug Delivery Systems; In Vitro Techniques; Male; Medicine, Chinese Traditional; Polyglutamic Acid; Rats; Rats, Sprague-Dawley; Solubility; Spectroscopy, Fourier Transform Infrared; Temperature; Water | 2020 |
Tanshinone IIA loaded chitosan nanoparticles decrease toxicity of β-amyloid peptide in a Caenorhabditis elegans model of Alzheimer's disease.
Topics: Abietanes; Alzheimer Disease; Amyloid beta-Peptides; Animals; Caenorhabditis elegans; Chitosan; Humans; Nanoparticles; Superoxide Dismutase | 2022 |
Targeted pH-responsive chitosan nanogels with Tanshinone IIA for enhancing the antibacterial/anti-biofilm efficacy.
Topics: Anti-Bacterial Agents; Biofilms; Chitosan; Humans; Hydrogen-Ion Concentration; Nanogels | 2023 |
Construction of carboxymethyl chitosan-based nanoparticles of hypoxia response for co-loading doxorubicin and tanshinone IIA.
Topics: Breast Neoplasms; Cell Line, Tumor; Chitosan; Doxorubicin; Drug Carriers; Female; Humans; Nanoparticles | 2023 |